Prader-Willi syndrome and growth hormone deficiency

Area of Science:

• Genetics
• Endocrinology
• Pediatrics

Background:

• Prader-Willi syndrome (PWS) is a rare, complex genetic disorder with variable clinical manifestations throughout life.
• Key features include infantile hypotonia, feeding issues, followed by hyperphagia and obesity, often linked to hypothalamic dysfunction.
• Hypothalamic dysfunction in PWS can lead to deficiencies in growth hormone (GH), thyroid-stimulating hormone (TSH), central adrenal insufficiency, and hypogonadism.

Purpose of the Study:

• To review the role and management of Growth Hormone (GH) therapy in patients with Prader-Willi syndrome (PWS).
• To highlight the benefits and contraindications of GH therapy in the context of PWS management.

Main Methods:

• Literature review of studies documenting GH secretion and IGF-1 levels in PWS patients.
• Analysis of the effects of GH therapy on growth, body composition, and neurodevelopment in PWS.
• Examination of recommended GH dosages and critical contraindications for initiating therapy.

Main Results:

• Studies consistently show reduced GH secretion, blunted GH response to stimulation, and low IGF-1 levels in PWS patients.
• GH therapy demonstrates significant benefits for growth, body composition, motor skills, and cognitive development in PWS.
• Recommended GH dosage is 0.5-1 mg/m2/day, with crucial contraindications including obstructive sleep apnea, adenotonsillar hypertrophy, severe obesity, and diabetes mellitus.

Conclusions:

• GH therapy is a valuable component of multidisciplinary management for genetically confirmed PWS patients.
• Careful patient selection, considering contraindications and integrating lifestyle measures, is essential for safe and effective GH treatment.
• GH therapy offers substantial improvements in key developmental and physical outcomes for individuals with Prader-Willi syndrome.